Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Learn more about the evolving role of CDK4/6 inhibitors to treat patients with HR-positive/HER2-negative breast cancer through a certified on-demand webcast, downloadable self-teaching slideset, and podcast.

Share

Program Content

Activities

CDK4_6 Inhibitors in HR+, HER2-Negative Breast Cancer
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Inhibiteurs de CDK4/6 cancer du sein HR+/HER2-
Conversations autour du cancer portant sur l'élargissement du paysage thérapeutique des inhibiteurs de CDK4/6 dans le traitement du cancer du sein HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2024

Expires: July 25, 2025

Inibidores de CDK4/6 em câncer de mama HR+/HER2-
Conversas sobre o câncer: o cenário terapêutico em expansão para inibidores de CDK4/6 em câncer de mama HR-positivo/HER2-negativo
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2024

Expires: August 18, 2025

Los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
Conversaciones sobre el cáncer de mama RH positivo/HER2 negativo en el panorama terapéutico en expansión de los inhibidores de CDK4/6
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2024

Expires: August 20, 2025

Activities

HR Positive HER2 Negative Breast Cancer at ASCO 2024
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2024

Expires: June 16, 2025

Activities

CDK4,6 Inhibition in Breast Cancer
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2024

Expires: July 08, 2025

Activities

CDK4,6 Inhibitors in Breast Cancer
Experts Answer Your Questions on CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 05, 2024

Expires: July 04, 2025

Inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
Des experts répondent à vos questions concernant les inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 09, 2024

Expires: August 08, 2025

Inibidores de CDK4/6 no câncer de mama HR+/HER2-
Especialistas respondem às suas perguntas sobre inibidores de CDK4/6 no câncer de mama HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2024

Expires: August 18, 2025

Los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
Los expertos responden a sus preguntas sobre los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2024

Expires: August 20, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation